Charles Schwab Investment Management Inc Protagonist Therapeutics, Inc Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 565,503 shares of PTGX stock, worth $25.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
565,503
Previous 525,653
7.58%
Holding current value
$25.4 Million
Previous $18.2 Million
39.53%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding PTGX
# of Institutions
247Shares Held
56.4MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$263 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$258 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$243 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$189 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$143 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.2B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...